Kymera Therapeutics, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Kymera Therapeutics, Inc. (KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics utilizing targeted protein degradation to selectively eliminate disease-causing proteins by harnessing the body's natural protein degradation machinery; its proprietary Pegasus platform supports a pipeline focused primarily on immunology and inflammation disorders, with additional programs in oncology. The company offers investigational oral degraders including KT-621, a first-in-class STAT6 degrader in Phase 1 trials for Th2-mediated diseases such as atopic dermatitis, asthma, chronic obstructive pulmonary disease, prurigo nodularis, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis, bullous pemphigoid and chronic spontaneous urticaria; KT-579, an IRF5 degrader in IND-enabling studies for autoimmune conditions including lupus, Sjögren’s syndrome, rheumatoid arthritis, inflammatory bowel disease, systemic sclerosis and dermatomyositis; and KT-485 (SAR447971), a second-generation IRAK4 degrader prioritized by partner Sanofi for clinical advancement in immuno-inflammatory diseases like hidradenitis suppurativa, atopic dermatitis, psoriasis, asthma and others. It also advances a CDK2 molecular glue degrader program in collaboration with Gilead Sciences targeting oncology indications such as breast cancer and other solid tumors where CCNE1 amplification drives resistance to CDK4/6 inhibitors. Founded in 2015 and headquartered in Watertown, Massachusetts, Kymera operates globally with partnerships including Sanofi for IRAK4 degraders outside oncology, providing milestone payments up to $975 million, U.S. co-commercialization option and profit-sharing, and royalties elsewhere; and Gilead for the CDK2 program, offering up to $750 million including $85 million upfront and option fees plus tiered royalties. Recent developments encompass the June 2025 Gilead alliance for CDK2, Sanofi's prioritization of KT-485 for clinical studies by year-end 2025 with a related $20 million preclinical milestone to Kymera, expansion of the immunology pipeline with the IRF5 program (KT-579) announced in May 2025 targeting rheumatic and autoimmune diseases, and positive Phase 1 data for KT-621 and prior IRAK4 degrader KT-474.
Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference
Kymera Therapeutics Announces Presentations on KT-621, a First-In-Class, Oral STAT6 Degrader, at the Society for Investigative Dermatology and American Thoracic Society Congresses
Kymera Therapeutics, Inc. (KYMR) Presents at Bank of America Global Healthcare Conference 2026 Transcript
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Kymera Therapeutics, Inc. (NASDAQ: KYMR)
Here Are Wednesday’s Top Wall Street Analyst Research Calls: Advanced Micro Devices, American Eagle Outfitters, GlobalFoundries, IAC, Merck, Palantir Technologies, Reddit, and More
Kymera Therapeutics to Participate in Upcoming May Investor Conferences
Kymera Therapeutics Presents New Preclinical IBD Data for KT-579, a First-in-Class, Oral IRF5 Degrader, at Digestive Disease Week
KYMR Q1 Earnings Top Estimates, Revenues Gain on GILD Collaboration
Kymera Therapeutics, Inc. (KYMR) Q1 2026 Earnings Call Transcript
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics Announces First Quarter 2026 Financial Results and Provides a Business Update
B. Metzler seel. Sohn & Co. AG Purchases New Holdings in Kymera Therapeutics, Inc. $KYMR
Kymera Therapeutics to Report First Quarter 2026 Financial Results on April 30, 2026
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells $374,185.23 in Stock
Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells $472,590.00 in Stock
KYMR Stock Up as FDA Grants Fast Track Designation to Asthma Drug
Kymera: 'Strong Buy' On Continued Success With KT-621 In Th2-Driven Disorders
Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma
KYMR Set to Earn Milestone Payment as GILD Secures License for KT-200